Eli Lilly and Company reported that the COVID-19 pandemic posed a negative impact on its second quarter sales and earnings on 30 July, with its three biggest products – Trulicity, Taltz and Jardiance – down or flat from the first quarter. But all three showed growth over the second quarter 2019 and Lilly maintains its overall trends are positive, citing 6% volume growth for the first six months of 2020 compared to the first half of 2019.
Lilly Points To Six-Month Growth Instead Of Pandemic Impacted Q2
Lilly argues the overall trend is positive, although the second quarter was down. Trial successes with Verzenio, Trulicity, Jardiance and mirikizumab offer additional growth potential.
More from Earnings
• By
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
• By
AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.
• By
The big pharma forecast a $400m expense this year related to tariffs, but those estimates only reflect medtech tariffs already announced, not potential pharma tariffs.
• By
Adstiladrin sales hit €70m in first full year on the market
More from Business
• By
Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.
• By
Cancer assets drove the highest percentage of biopharma alliance dealmaking in 2024, tripling the frequency of the next highest therapeutic category, neurology.
• By
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.